Sana Biotechnology, Inc. (NASDAQ:SANA) Shares Sold by Principal Financial Group Inc.

Principal Financial Group Inc. trimmed its position in Sana Biotechnology, Inc. (NASDAQ:SANA) by 52.0% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 12,364 shares of the company’s stock after selling 13,417 shares during the quarter. Principal Financial Group Inc.’s holdings in Sana Biotechnology were worth $51,000 at the end of the most recent quarter.

Other large investors also recently made changes to their positions in the company. Wilmington Savings Fund Society FSB acquired a new stake in Sana Biotechnology in the third quarter valued at approximately $29,000. Stifel Financial Corp purchased a new stake in shares of Sana Biotechnology during the third quarter worth about $43,000. EP Wealth Advisors LLC bought a new position in Sana Biotechnology during the 3rd quarter valued at $45,000. Blue Trust Inc. raised its stake in Sana Biotechnology by 1,246.6% during the third quarter. Blue Trust Inc. now owns 13,129 shares of the company’s stock valued at $55,000 after buying an additional 12,154 shares in the last quarter. Finally, Cornercap Investment Counsel Inc. acquired a new position in Sana Biotechnology in the third quarter worth $67,000. Institutional investors and hedge funds own 88.23% of the company’s stock.

Sana Biotechnology Stock Down 5.7 %

Shares of Sana Biotechnology stock opened at $1.65 on Wednesday. The stock has a market cap of $368.39 million, a PE ratio of -1.18 and a beta of 1.45. The business has a fifty day simple moving average of $2.38 and a 200-day simple moving average of $4.07. Sana Biotechnology, Inc. has a 12 month low of $1.52 and a 12 month high of $12.00.

Sana Biotechnology (NASDAQ:SANA) last posted its earnings results on Friday, November 8th. The company reported ($0.25) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.26) by $0.01. Analysts expect that Sana Biotechnology, Inc. will post -1.16 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on SANA. JMP Securities downgraded Sana Biotechnology from an “outperform” rating to a “market perform” rating in a report on Tuesday, November 5th. HC Wainwright reiterated a “buy” rating and issued a $8.00 price target on shares of Sana Biotechnology in a research report on Wednesday, November 27th.

About Sana Biotechnology

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.